RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial

Olga Holubovska, Pavlo Babich, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Lutz Mueller, Aartjan J.W. te Velthuis, Victor Margitich, Andrew Goy

Research output: Contribution to journalArticlepeer-review

Abstract

Highlights: What are the main findings? Enisamium, administered in conjunction with standard care, demonstrated clinical efficacy in hospitalized adults with moderate COVID-19 requiring supplemental oxygen. In patients with moderate COVID-19 requiring supplemental oxygen, treatment with enisamium led to a significant reduction in the time to improvement and a reduction in symptoms compared to placebo, particularly when administered within 4 days of COVID-19 symptom onset. What is the implication of the main finding? Enisamium presents a promising treatment option for individuals with moderate COVID-19, offering faster recovery and shorter hospital stays. Early administration of enisamium, within 4 days of symptom onset, may lead to more rapid clinical improvement, underscoring the importance of early intervention in managing COVID-19 cases. Enisamium is an orally available therapeutic that inhibits influenza A virus and SARS-CoV-2 replication. We evaluated the clinical efficacy of enisamium treatment combined with standard care in adult, hospitalized patients with moderate COVID-19 requiring external oxygen. Hospitalized patients with laboratory-confirmed SARS-CoV-2 infection were randomly assigned to receive either enisamium (500 mg per dose, four times a day) or a placebo. The primary outcome was an improvement of at least two points on an eight-point severity rating (SR) scale within 29 days of randomization. We initially set out to study the effect of enisamium on patients with a baseline SR of 4 or 5. However, because the study was started early in the COVID-19 pandemic, and COVID-19 had been insufficiently studied at the start of our study, an interim analysis was performed alongside a conditional power analysis in order to ensure patient safety and assess whether the treatment was likely to be beneficial for one or both groups. Following this analysis, a beneficial effect was observed for patients with an SR of 4 only, i.e., patients with moderate COVID-19 requiring supplementary oxygen. The study was continued for these COVID-19 patients. Overall, a total of 592 patients were enrolled and randomized between May 2020 and March 2021. Patients with a baseline SR of 4 were divided into two groups: 142 (49.8%) were assigned to the enisamium group and 143 (50.2%) to the placebo group. An analysis of the population showed that if patients were treated within 4 days of the onset of COVID-19 symptoms (n = 33), the median time to improvement was 8 days for the enisamium group and 13 days for the placebo group (p = 0.005). For patients treated within 10 days of the onset of COVID-19 symptoms (n = 154), the median time to improvement was 10 days for the enisamium group and 12 days for the placebo group (p = 0.002). Our findings suggest that enisamium is safe to use with COVID-19 patients, and that the observed clinical benefit of enisamium is worth reporting and studying in detail.

Original languageEnglish (US)
Pages (from-to)202-217
Number of pages16
JournalAdvances in Respiratory Medicine
Volume92
Issue number3
DOIs
StatePublished - Jun 2024

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Keywords

  • Amizon
  • COVID-19
  • FAV00A
  • RNA polymerase
  • SARS-CoV-2
  • antiviral
  • clinical trial

Fingerprint

Dive into the research topics of 'RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial'. Together they form a unique fingerprint.

Cite this